Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07831824) titled 'Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
Primary Sponsor: Lantheus Medical Imaging
Condition:
Prostate Cancer
Intervention:
Drug: [68Ga]-LNTH-2401
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: September 30, 2026
Target Sample Size: 408
Countries of Recruitment:
United States
To know more, visi...